Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Pembrolizumab |
Indication/Tumor Type | osteosarcoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | osteosarcoma | sensitive | Pembrolizumab | Case Reports/Case Series | Actionable | In a Phase II trial, Keytruda (pembrolizumab) treatment resulted in 1 partial response in 2 patients with CD274 (PD-L1)-positive osteosarcoma (J Clin Oncol 35, no. 15_suppl (May 20, 2017) 11008; NCT02301039). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses. | Full reference... |